Syngene's Bengaluru-based facility gets 'NAi' status from US FDA

The inspection concluded successfully, with the facility found to be in compliance with the required regulations.

The inspection resulted in zero observations and no Form 483 was issued. The inspection has been classified as 'no action indicated' (NAI).

'The company remains commitment to high operating standards and rigorous compliance with global regulatory requirements across all its operations,' Syngene said in a statement.

Syngene International is an integrated research, development, and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors.

On a consolidated basis, net profit of Syngene International declined 2.81% to Rs 183.30 crore while net sales rose 11.03% to Rs 1018 crore in Q4 March 2025 over Q4 March 2024.

The scrip had lost 1.57% to end at Rs 652.50 on the BSE on Friday.

Powered by Capital Market - Live News